Arrivobio Raises $45M In Series B Financing To Advance Pipeline

Nov 29, 2023•about 2 years ago

Amount Raised

$45 Million

Round Type

series b

MorrisvilleTherapeuticsBiotechnologyHealth Care

Investors

ArrivoRex Health VenturesSolas Bio Ventures Emerging Healthcare Fund, L.P.Orlando Health Ventures

Description

Arrivo BioVentures today announced the closing of an oversubscribed Series B preferred financing round, totaling $45.25 million in committed capital, bringing the total raised since the company’s inception to $100M.

Company Information

Company

ArrivoBio

Location

Morrisville, New York, United States

About

SP-624 is a small molecule that selectively activates the SIRT6 enzyme, a novel epigenetic mechanism known to modulate gene expression, metabolism and DNA repair. Recent published literature suggests that human females and males exhibit gene expression changes in opposite directions when depressed.1 The results of Arrivo’s Phase 2 study with SP-624 appear to support this finding by demonstrating that female subjects on SP-624 experienced early and robust alleviation of depressive symptoms, unlike male patients in the study.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends